Paper Details

  1. Home
  2. Paper Details

Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.

Author: ChongKelly, KimSharon, LemboAnthony, PimentelMark, ShahEric

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This study examines the side effects of medications used to treat irritable bowel syndrome (IBS) with diarrhea and constipation. It looks at treatments recommended by the American College of Gastroenterology and uses a systematic review to assess the number of patients who experience harm from each medication.
Paper Details　
Original Abstract of the Article :
Current treatment options for irritable bowel syndrome are limited and often poorly studied. A select few drugs have been studied in irritable bowel syndrome, and the number needed to treat is frequently used to assess the relative efficacy of these treatments. However, side effects are an important...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.amjmed.2011.08.026

データ提供：米国国立医学図書館（NLM）

Irritable Bowel Syndrome: Balancing Benefits and Risks in Pharmacotherapy

Gastroenterology, the study of the digestive system, often tackles the complexities of chronic conditions that impact gut health. This research investigates the potential benefits and harms associated with various pharmacotherapeutic approaches for irritable bowel syndrome (IBS), a common disorder characterized by abdominal pain and altered bowel habits. The study focuses on evaluating the number needed to harm (NNH) for different drugs used in treating IBS, providing insights into the potential risks associated with these medications.

Navigating the Risks and Benefits of IBS Medications

The study systematically reviewed and meta-analyzed clinical trials of IBS patients receiving various drug interventions, calculating the NNH for each treatment. This analysis provides a quantitative estimate of the potential risks associated with these medications, helping clinicians weigh the potential benefits against the potential harms. The study's findings offer valuable information for making informed decisions about IBS pharmacotherapy.

Informed Decision-Making in IBS Management

This research emphasizes the importance of a balanced approach to IBS management, considering both the potential benefits and risks of pharmacotherapeutic interventions. By providing quantitative estimates of the NNH for different medications, the study empowers clinicians to make more informed decisions about treatment options, balancing the potential for improvement with the potential for adverse effects. This research highlights the importance of ongoing research in developing safer and more effective treatments for IBS, ultimately improving the lives of individuals living with this chronic condition.

Dr.Camel's Conclusion

This study, like a wise desert guide navigating a treacherous landscape, sheds light on the potential risks associated with various IBS medications. By providing quantitative estimates of the NNH, it helps clinicians weigh the potential benefits against the potential harms, ensuring more informed decision-making in managing this challenging condition. This research reminds us that navigating the complexities of healthcare requires careful consideration of all factors, balancing potential benefits with potential risks to optimize patient outcomes.

Date :
  1. Date Completed 2012-05-14
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

22444104

DOI: Digital Object Identifier

10.1016/j.amjmed.2011.08.026

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.